Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Abiraterone (Zytiga)This afternoon the FDA approved Ortho Biotech’s abiraterone acetate (Zytiga) in combination with prednisone for the treatment of castrate resistant prostate cancer in patients who have received prior chemotherapy with docetaxel.

Abiraterone was filed on December 20th, 2010 and received fast track designation, so the FDA approval comes 2 months ahead of the expected PDUFA date of June 20th.

It represents another exciting advance for this disease after what Dr Bernard Tombal described as a “Grand Cru” year for prostate cancer in 2010 following the successive launches of cabazitaxel (Jevtana), sipuleucel-T (Provenge) and denosumab (Xgeva), the first since docetaxel (Taxotere) was approved back in 2006 for chemotherapy naive metastatic disease.

I’ve written much about the clinical data from various oncology meetings over the last nine months such as ESMO last September and EAU in Vienna last month.  You can check out the data in the related posts below.

The big question on everyone’s mind, though, has been price.  Docetaxel is now generically available, Sanofi-Aventis’s cabazitaxel is around $6K per cycle (assumes ~$48K if 6 cycles are completed), Dendreon’s sipuleucel-T is $93K for three infusions.

Ruth Coxeter of CNBC Health Sciences was the first to tweet the confirmed abiraterone price of $5K per month, with a median of eight months of therapy.  This gives a treatment price of  ~$40K, which I think is very fair, although some patients will obviously take it for longer than that.

Ruth Coxeter, CNBC Pharma's Market

For those interested in the press release, you can read more here.

What does this approval mean?

abiraterone acetate (Zytiga)

For men with castrate resistant prostate cancer (CRPC) who have previously received chemotherapy, there is now a new treatment option for them to choose other than more chemotherapy with cabazitaxel in the form of easy to take pills (four per day).

The data from the 302 trial in the pre-chemo setting is expected later this year and is expected to be better than the 3.9 months overall survival benefit seen in the post chemotherapy setting reported at EAU last month.

In the analysis for the FDA approval, the overall survival benefit had increased further according to Ortho Biotech:

“In an updated analysis, results were consistent with those from the interim analysis with a 4.6 month difference between the two arms in median survival (15.8 months vs. 11.2 months [HR = 0.74]).”

At the European Association of Urology meeting earlier this year, Dr Johann De Bono (Royal Marsden) told a packed audience that the data for the circulating tumour cells (CTCs) would finally be available at the ASCO annual meeting in June.  It will be interesting to see whether this is a better surrogate measure of response than PSA. With the American Urology Association meeting coming up in a few weeks in DC, not doubt there will be more to discuss then.

All in all, it is good to see new treatment options emerge for the treatment of castrate resistant prostate cancer.

7 Responses to “Abiraterone now approved as Zytiga by the FDA in castrate resistant prostate cancer”

  1. Dimeded

    These are some great insights! Just thought I’d fill you in on a new online CME from DIME that lets you browse and store info at the point of care while you earn CME credit.


    Hope you find this information helpful!

  2. Website Designer Riyadh

    Yeah this information is very helpful.. I will share this information in social networking sites.. Then it will reach to everyone.. I have heard that this price is reasonable.. Thanks for sharing this information with us..

  3. Karenannestevens

    Does the patient get off Lupron with this drug?

  4. EXEL - Exelixis, Inc - MyStockBuddy Stock Forums

    […] proven. Alpharadin on fast track to FDA prostate cancer approval in 2012 | Biotech Strategy Blog Ortho Biotech's abiraterone Zytiga approved in advanced prostate cancer | Pharma Strategy Blog Even though XL184 works on a different mechanism (VEGF/MET inhibition) compared to, let's say, […]

  5. The Medical Physicist

    Sm-153 and Sr-89 are very overlooked products once patients progress beyond this stage.  If the proper patient is chosen, someone who would be functional without the pain, the results are quite good.  Sm-153 and Sr-89 seem to be roughly equivalent in terms of what they do, we prefer Sm-153 because it has a very short half life, so the patient’s marrow is not exposed to days of radiation.  We had a woman last month who was able to resume golfing and and reduce morphine to almost nothing a couple of weeks after radiotherapy.  In fact, she started to complain about arthritic pain again, having forgotten about her bone pain.  It’s a pretty cost effective alternative– but it’s imperative to pick the right patients.  With the excitement over these four new products, the handful of patients who may benefit from radiotherapy may be forgotten.  Certainly radiotherapy is not an alternative to the new exciting products, but it probably has a role still for the appropriate patient.

  6. Dr. CATHERINE Atkins

    My husband is participating in a clinical trial of this drug….why are there clinical trials if drug has been fda approved…study at hackensack medical center. Dr.Catherine Atkins.

Comments are closed.

error: Content is protected !!